PAM 50 in breast cancer
Reading File
search_medical_text
PAM50 breast cancer intrinsic subtypes molecular classification
search_medical_text
PAM50 ROR score prognosis treatment breast cancer clinical use
GradeResponse
GradeResponse
Here is a comprehensive overview of PAM50 in breast cancer:
PAM50 (Prosigna) in Breast Cancer
What Is PAM50?
PAM50 is a 50-gene expression signature used to classify breast cancer into intrinsic molecular subtypes and generate a quantitative risk score. The commercial assay based on PAM50 is called Prosigna, which uses NanoString nCounter technology on formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
The Four Intrinsic Subtypes
PAM50 classifies tumors into one of four molecular subtypes, each with distinct biology, prognosis, and therapeutic implications:
| Subtype | Key Features | Prognosis |
|---|---|---|
| Luminal A | ER+, low proliferation, low-grade | Best; low recurrence risk |
| Luminal B | ER+, higher proliferation, may be HER2+ | Intermediate; higher recurrence risk than Luminal A |
| HER2-enriched | HER2 overexpression (may be ER−) | Intermediate-poor without anti-HER2 therapy |
| Basal-like | ER−/PR−/HER2− (triple-negative overlap) | Worst overall; chemo-sensitive |
A fifth category — Normal-like — is sometimes reported but has uncertain clinical significance.
The Risk of Recurrence (ROR) Score
PAM50's primary clinical output is the Risk of Recurrence (ROR) score, a continuous 0–100 score integrating:
- The molecular subtype assignment
- Proliferation score (derived from the 50 genes)
- Tumor size (in the Prosigna version)
ROR is stratified into:
- Low risk: ROR < 40 (approximately; thresholds vary by nodal status)
- Intermediate risk: ROR 40–60
- High risk: ROR > 60
According to Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer (p. 11), the ROR score is most validated through retrospective analyses of prospective randomized trials and population-based studies — distinguishing it from Oncotype DX, which has a prospective trial (TAILORx). There are currently no prospective randomized clinical utility trials specific to Prosigna/PAM50.
Clinical Indications
PAM50/Prosigna is primarily used in HR+, HER2−, early-stage breast cancer to guide adjuvant chemotherapy decisions:
- Node-negative disease: Identifies patients at low risk who can safely forgo chemotherapy
- Node-positive (1–3 nodes): Can stratify patients at high vs. low risk of late recurrence (years 5–10), helping guide extended endocrine therapy decisions (e.g., adding abemaciclib or continuing aromatase inhibitor)
Key validated datasets include:
- ABCSG-8 and ATAC trials: validated ROR for predicting distant recurrence in postmenopausal ER+/HER2− patients
- TransATAC and AZURE studies: further validation of late recurrence prediction
PAM50 vs. Other Genomic Tests
| Feature | PAM50 (Prosigna) | Oncotype DX (RS) | Mammaprint |
|---|---|---|---|
| Genes | 50 | 21 | 70 |
| Technology | NanoString | RT-PCR | Microarray |
| Output | Subtype + ROR score | Recurrence Score (0–100) | Binary (High/Low) |
| Prospective trial | No | Yes (TAILORx, RxPONDER) | Yes (MINDACT) |
| Node-positive data | Yes (1–3 nodes) | Yes (RxPONDER) | Yes (MINDACT) |
| Late recurrence prediction | Strong | Moderate | Moderate |
PAM50 is particularly notable for its late recurrence prediction (beyond 5 years), which is clinically relevant when deciding on extended adjuvant endocrine therapy.
Guideline Recommendations
- ASCO 2022 / NCCN: Prosigna is listed as an option for multigene assay testing in HR+/HER2−/node-negative and select node-positive patients, particularly postmenopausal women
- The St. Gallen Consensus and ESMO guidelines recognize PAM50 as a validated genomic tool, especially for identifying Luminal A vs. Luminal B biology beyond standard IHC surrogates
- Preferred in some European health systems (UK NHS, some Nordic countries) where it has regulatory approval and health-technology assessment support
Key Clinical Pearl: IHC vs. PAM50 Subtyping
Clinical IHC-based subtyping (using ER, PR, HER2, Ki-67) is a surrogate for intrinsic subtyping. PAM50 reclassifies a meaningful proportion of patients:
- ~20–30% of IHC "Luminal B" tumors are reclassified as Luminal A by PAM50
- Some IHC Luminal A tumors are upstaged to Luminal B
- This reclassification has direct implications for chemotherapy recommendation and prognosis counseling
Summary
PAM50/Prosigna serves two main functions in clinical breast oncology:
- Molecular subtype classification — providing biologic insight beyond IHC
- ROR score — quantifying 10-year distant recurrence risk to personalize adjuvant therapy decisions
Its strongest niche is late recurrence prediction in postmenopausal HR+ early breast cancer, though the absence of a prospective utility trial remains a limitation compared to Oncotype DX.
This is a shared conversation. Sign in to Orris to start your own chat.